Business
Celcuity to Present Preclinical Data on Therapeutic Effects of Gedatolisib in Gynecological Cancer Models at AACR Annual Meeting 2023
MINNEAPOLIS, MN / ACCESSWIRE / March 15, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted
About this update from Celcuity Inc.
[{"type":"text","content":"MINNEAPOLIS, MN / ACCESSWIRE / March 15, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced publication of an abstract reporting data from preclinical studies evaluating gedatolisib and other PI3K/AKT/mTOR inhibitors in endometrial, ovarian, and cervical cancer cell lines. A poster will be presented at the 2023 Annual Meeting of the American Association for Cancer Research (AACR), which will be held April 14-19, 2023 in Orlando, Florida.The abstract and poster presentation describe the potency and efficacy of gedatolisib and other PI3K/AKT/mTOR inhibitors using cell viability, cell proliferation, and flow cytometry assays in endometrial, ovarian, and cervical cancer cell lines.\"We are excited to report preclinical data describing gedatolisib's potent therapeutic effects on gynecological cancer models. These results further demonstrate gedatolisib's differentiated mechanism of action,\" said Brian Sullivan, Celcuity's Chief Executive Officer and co-founder. \"Along with the preclinical data for prostate cancer models presented in February at the ASCO-GU meeting, these results provide support and rationale for our future clinical development plans.\"Presentation Details:Title: Gedatolisib, a well-tolerated pan-PI3K/mTOR inhibitor, exhibits potent therapeutic effects on endometrial cancer models regardless of their PI3K pathway mutational statusSession Title: Novel Antitumor Agents, PI3K/AKT Inhibitors, Proteasome Inhibitors, and TopoisomerasesDate and Time: Tuesday, April 18, 2023, 1:30-5:30 p.m. ETLocation: Poster Section 15Poster Board Number: 6Abstract Number: 4928The abstracts are available online at AACR 2023 in advance of the 2023 AACR Annual Meeting. The poster will be available online on the publications page of the Celcuity website following the poster presentation.About GedatolisibGedatolisib is an investigational, pan-PI3K and mTOR inhibitor with low nanomolar potency for all Class I PI3K isoforms and mTORC1 and mTORC2. Its mechanism of action and pharmacokinetic properties are highly differentiated from other therapies that target PI3K or mTOR alone or together. Inhibiting all four Class I PI3K isoforms and mTOR limits the potential development of drug resistance compared to isoform-specific PI3K or mTOR specific inhibit...